Cambrex
March 16, 2023
Pharmaceutical companies are looking to pediatric indications of approved adult dosage forms (ADFs) to sustain and fuel growth. The desire to develop pediatric dosage forms (PDFs) of drugs with existing adult indications has two main drivers: (1) the US Food and Drug Administration’s (FDA’s) role in limiting off-label use in pediatric patients, which aligns with the FDA’s role in ensuring the safety and efficacy of approved products for all patients; and (2) sustaining revenue growth through ...
Pharmaceutical companies are looking to pediatric indications
of approved adult dosage forms (ADFs) to sustain and fuel
growth. The desire to develop pediatric dosage forms (PDFs)
of drugs with existing adult indications has two main drivers: (1)
the US Food and Drug Administration’s (FDA’s) role in limiting
off-label use in pediatric patients, which aligns with the FDA’s
role in ensuring the safety and efficacy of approved products for
all patients; and (2) sustaining revenue growth through pediatric
exclusivity that typically adds 180 days of intellectual property
protection and thus almost 6 additional months of branded drug
sales, which in some cases could translate to billions of dollars in
revenue.
#scale-up #manufacturing #pediatric drug development #dosage form
Parmaceutical manufacturer
Feb. 27, 2023
Dr. Klaus Pollinger and Dr. Martina Breuer, Aenova Group, explore the challenges of development and commercial manufacturing of oral solid dosage forms, from a CDMO perspective.
#HPAPI #CDMO #manufacturing #Solid dosage forms #R&D #production
MySTYL'One
July 11, 2022
The present works demonstrated the feasibility of producing high drug load minitablets from a cohesive, electrostatic–prone fine drug powder. The study is available in the PAPERS section.
Find others papers here and learn about
#STYL'One Nano #manufacturing #parameters #database #optimization
MySTYL'One
June 23, 2022
The present works detail an ambitious “Digital Medicines Manufacturing" (DM²) program, which aims to transform medicines development and manufacturing productivity, driving patient-centric supply through the creation and adoption of Industrial Digital Technologies (IDTs). Medelpharm is part of this innovative project. The 2 posters talking on it are available in the PAPERS section.
Find others papers here and learn about
The present works detail an ambitious “Digital Medicines Manufacturing" (DM²) program, which aims to transform medicines development and manufacturing productivity, driving patient-centric supply through the creation and adoption of Industrial Digital Technologies (IDTs). Medelpharm is part of this innovative project. The 2 posters talking on it are available in the PAPERS section.
Find others papers here and learn about
#STYL'One Nano #manufacturing #parameters #database #optimization
www.korsch.com
Sept. 6, 2021
“The manufacturing of multilayer tablets may seem to be simple duplications of the basic single-layer compression cycle, but in reality, the process is far more complicated. In this article, KORSCH outlines the key considerations in the production of multilayer tablets and defines the key parameters for multilayer process optimization.” Click here for full article